Myriad Genetics partners with Epic to make genetic testing more accessible to more patients by integrating electronic health records (EHR)

Myriad Genetics, Inc.

Myriad Genetics, Inc.

  • Healthcare suppliers can simply order Myriad genetic checks for greater than 250 million sufferers throughout the Epic . community

  • Partnership advances Myriad’s progress plan to broaden customer-centric, technology-enabled enterprise capabilities with greater than 600 human digital data integrations this 12 months

Salt Lake Metropolis, June 23, 2022 (Globe Newswire) – Myriad Genetics, Inc.. (NASDAQ: MYGN), the chief in genetic testing and precision drugs, at the moment introduced a partnership with Epic, the industry-leading healthcare software program firm, to combine Myriad’s full suite of genetic testing with Epic’s increasing community of 600,000 physicians and greater than 250 million sufferers. .

The combination creates a seamless, end-to-end workflow resolution for healthcare suppliers to request Myriad checks and assessment outcomes immediately inside their every day Epic platform with out extra steps or guide ordering processes. Epic allows the safe change of knowledge between healthcare organizations that take care of sufferers.

With the flexibility to assessment related well being data, order checks, and obtain outcomes domestically at Epic, suppliers could have the crucial genetic insights and associated data they should obtain higher well being outcomes and enhance affected person expertise. Sufferers can even be capable of simply entry Myriad take a look at outcomes and different well being data immediately by means of their EHR portal.

“Simplifying the genetic testing course of by making it extra intuitive and interoperable with digital well being data is a vital part of our mission to advance the well being and well-being of all,” mentioned Paul J. Diaz, President and CEO of Myriad Genetics. “Our collaboration with Epic displays our technique of partnering with different healthcare {industry} leaders in order that we will advance precision drugs collectively. Rising entry to genetic insights and integrating our checks into Epic’s huge community of healthcare programs is a crucial step ahead to raised serve sufferers and healthcare suppliers.”

As a part of its transformation and progress plan, Myriad is specializing in new customer-centric and technology-enabled instruments to facilitate the genetic testing course of for sufferers and clinicians. With the current launch of Myriad’s Exact Oncology Options, suppliers can now submit a single request for numerous checks and get ends in a well timed method by means of a unified on-line portal. Now, by partnering with Epic, Myriad is increasing its efforts to assist clinicians and well being programs entry genetic testing sooner and extra conveniently throughout the platform they use day-after-day.

“Genetic testing and precision drugs are saving lives,” mentioned Alan Hutchison, vp of inhabitants well being at Epic. “By this relationship, we carry genetic insights to the purpose of care at scale, offering suppliers and sufferers with the data they should make knowledgeable and well timed choices.”

Myriad’s integration with Epic is anticipated to start later this 12 months.

About Numerous Genetics
Myriad Genetics is a number one genetic testing and precision drugs firm devoted to advancing the well being and well-being of all. Myriad develops and commercializes genetic checks that assist assess the chance of illness development or illness development and information therapy choices throughout medical specialties the place genetic insights can dramatically enhance affected person care and decrease well being care prices. Quick Firm named Myriad amongst Probably the most revolutionary firms on the planet for 2022. For extra data, go to www.myriad.com.

Myriad, Brand Myriad, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, MyRisk MyRisk, MyRisk Hereditary Most cancers, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, PreciseI, FirstGene, Well being. . GeneSight and EndoPredict are emblems or registered emblems of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. all rights are save.

Secure Harbor Assertion
This press launch incorporates “forward-looking statements” throughout the that means of the Non-public Securities Litigation Reform Act of 1995, together with statements concerning the Firm’s merger of genetic testing with the Epic community of physicians and sufferers and the anticipated timing of the merger; The corporate’s progress plan to broaden customer-centric, technology-enabled enterprise capabilities with greater than 600 digital data integrations this 12 months; Anticipated advantages from the combination, together with that the combination will create a complete workflow resolution for healthcare suppliers to order numerous checks and assessment outcomes immediately with their every day Epic workflows, offering suppliers with necessary genetic insights and related data they should obtain wholesome outcomes Higher and improved affected person expertise, permitting sufferers to simply entry their Myriad take a look at outcomes immediately from their EHR portal; and the corporate’s strategic imperatives beneath the title “About Myriad Genetics”. These “forward-looking statements” are administration’s present expectations of future occasions and are topic to a variety of dangers and uncertainties that would trigger precise outcomes to vary materially and adversely from these proven within the forward-looking statements. These dangers embrace, however usually are not restricted to: the uncertainties related to COVID-19, together with its potential results on the Firm’s operations, the demand for its services and products, and the Firm’s means to function its enterprise effectively and flexibly; The chance that gross sales and revenue margins will decline for the corporate’s present molecular diagnostics checks or that the corporate could not be capable of run its enterprise on a worthwhile foundation; Dangers associated to the Firm’s means to generate enough income from its current product portfolio or in launching and advertising and marketing new checks; Dangers associated to modifications in state or personal insurers’ protection and reimbursement ranges for the Firm’s checks or the Firm’s means to acquire compensation for its new checks at ranges just like its current checks; dangers associated to elevated competitors and the event of latest competitors checks and companies; The chance that the corporate won’t be able to develop or obtain industrial success for added molecular diagnostic checks in a well timed method, or in any respect; The chance that the Firm won’t achieve growing new markets for its molecular diagnostic checks, together with the Firm’s means to generate profitable income outdoors the USA; the chance that licenses for the know-how underlying the Firm’s molecular diagnostics checks and any future checks could also be terminated or can’t be held on passable phrases; Dangers associated to delays or different issues associated to the operation and development of the Firm’s laboratory testing amenities; Dangers associated to public concern about genetic testing basically or firm testing particularly; dangers associated to regulatory or enforcement necessities in the USA and overseas nations and modifications within the construction of the well being care system or well being care cost programs; Dangers associated to the Firm’s means to accumulate new licenses or institutional collaborations and to accumulate or develop new applied sciences or companies on passable phrases, if any; Dangers associated to the Firm’s means to efficiently combine and profit from any applied sciences or companies it licenses, acquires or develops; Dangers associated to the Firm’s expectations about potential market alternatives for the Firm’s present and future merchandise; the chance that the Firm or its licensors won’t be able to guard it or that third events will violate the proprietary strategies upon which the Firm’s checks are based mostly; the chance of claims of patent infringement or challenges to the validity of the corporate’s patents; Dangers associated to modifications in mental property legal guidelines masking the corporate’s molecular diagnostic checks, patents or enforcement, in the USA and overseas nations; dangers associated to safety breaches, information loss and different disruptions, together with cyber assaults; the dangers of latest, altering, and aggressive applied sciences and laws in the USA and internationally; the chance of the Firm’s lack of ability to adjust to its monetary working covenants beneath the Firm’s credit score or lending agreements; Dangers associated to materials weak point associated to basic IT controls, together with their influence and the Firm’s remedial plan, and its means to attain and preserve efficient disclosure controls and procedures and inside management over monetary reporting; dangers associated to present and future litigation, together with skilled or product legal responsibility claims; and different elements mentioned beneath “Threat Components” in Part 1A of the Firm’s Annual Report on Kind 10-Ok filed with the Securities and Alternate Fee on February 25, 2022, in addition to any updates to those danger elements offered now and again specified within the firm’s quarterly stories on Kind 10-Q or present stories on Kind 8-Ok. The reported variety of docs and sufferers within the Epic community was offered by Epic.

Media contact:
Megan Manzari
(385) 318-3718
Megan.Manzari@myriad.com

Investor contact:
Nathan Smith
(801) 505-5067
Nathan.Smith@myriad.com